Farxiga (Dapagliflozin) Cost in Montana 2026: Pricing, Insurance, and Savings Options

Farxiga is the brand name for dapagliflozin, an oral SGLT2 (sodium-glucose cotransporter-2) inhibitor made by AstraZeneca. It is dispensed as a 5 mg or 10 mg once-daily tablet. As of this writing, no FDA-approved generic dapagliflozin is available in the United States, which is the single biggest reason cash-pay prices stay high nationwide.

The useful question for a Montana patient is usually not "what does Farxiga cost," because that number moves with your insurance plan, pharmacy, and whether Montana Medicaid's preferred drug list currently excludes it. The more answerable question is: which of the facts below are fixed by federal approval and clinical guidelines, and which ones you must re-check yourself before making a decision, because they change on a timeline the FDA does not control.

This article separates those two categories rather than presenting a single price as if it applies to everyone.

The direct answer

Farxiga's price in Montana without insurance is set by AstraZeneca's list price and typical pharmacy markups, which commonly place brand-name SGLT2 inhibitors in the several-hundred-dollars-per-month range nationally; the exact current cash price at a specific Montana pharmacy should be confirmed directly, since it changes and was not independently verified for this article. Montana Medicaid coverage of dapagliflozin, commercial insurer tier placement, and manufacturer savings-card terms are all date-sensitive facts, not fixed facts, and each should be re-verified at the time you fill a prescription rather than assumed from any published figure, including the ones in this piece.

What is fixed: FDA-approved uses

Dapagliflozin's FDA-approved indications, per the drug's official FDA labeling information (available through the FDA's drug database), include:

• Type 2 diabetes, as an adjunct to diet and exercise to improve glycemic control
• Heart failure, to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with reduced or preserved ejection fraction
• Chronic kidney disease, to reduce the risk of sustained decline in kidney function, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure

These indications came from large cardiovascular and renal outcomes trials, commonly referenced in the literature as DAPA-HF, DAPA-CKD, and DECLARE-TIMI 58. The general direction of these trials (reduced heart failure hospitalization and slowed kidney function decline compared with placebo) is well established in cardiology and nephrology practice. This article does not reproduce the exact hazard ratios or confidence intervals from those trials, because the specific citation links available for this draft could not be independently confirmed as pointing to the correct papers. If you need the precise trial numbers for a clinical or insurance-appeal document, pull them directly from the published trial (search DAPA-HF, DAPA-CKD, or DECLARE-TIMI 58 on PubMed or ClinicalTrials.gov) rather than citing a secondhand summary.

A related SGLT2 inhibitor trial sometimes cited alongside dapagliflozin's kidney data is CREDENCE, which studied canagliflozin, a different SGLT2 inhibitor, not dapagliflozin. It is reasonable evidence for a class effect in diabetic kidney disease but should not be presented as dapagliflozin-specific data.

What is not fixed: price, formulary tier, and Medicaid status

Everything below changes on a schedule set by insurers, state Medicaid agencies, and pharmacies, not by the FDA. Treat none of it as permanent.

Cash price. Brand-name Farxiga without insurance is expensive relative to generic diabetes drugs like metformin, and Montana does not have unusually cheap or unusually expensive pharmacy pricing compared with other states, but a specific current dollar figure needs to come from GoodRx, a specific pharmacy, or AstraZeneca directly rather than from a fixed number in an article, since pharmacy cash prices are renegotiated and discount-card pricing changes frequently.

Montana Medicaid coverage. Whether Montana Medicaid's preferred drug list covers dapagliflozin, requires prior authorization, or excludes the SGLT2 inhibitor class entirely is a policy detail that changes with budget cycles and periodic PDL reviews. Confirm current status directly with Montana Medicaid or a participating pharmacy rather than relying on a stated coverage rule, because Medicaid formularies are revised on their own schedule and an outdated claim here would misinform a reader relying on it for a real prescription decision.

Commercial insurance tier placement. Blue Cross Blue Shield of Montana, PacificSource, and Montana Health Co-op plans set their own formulary tiers annually. Whether Farxiga sits on a preferred or non-preferred tier, and what step-therapy requirements apply (commonly, trying metformin first for diabetes, or documenting an ACE inhibitor/ARB trial for CKD, consistent with how SGLT2 inhibitors are generally positioned in the American Diabetes Association's Standards of Care for patients with established cardiovascular, heart failure, or kidney disease), should be confirmed against your specific plan's current formulary document, since tier placement can change at the start of a new plan year.

Manufacturer savings card and patient assistance. AstraZeneca has historically offered a commercial copay savings card for Farxiga and a separate income-based patient assistance program (AZ&Me) for uninsured patients. Copay card caps, eligibility rules (typically excluding patients on Medicare, Medicaid, Tricare, or VA benefits), and AZ&Me income thresholds are set and revised by AstraZeneca, not by regulators, and can change without notice. Confirm current terms directly on AstraZeneca's savings program page before assuming a specific copay amount or income cutoff.

Compounded dapagliflozin: what 503A status actually means

When a patient's clinical needs cannot be adequately met by a commercially available dapagliflozin formulation, Section 503A of the Federal Food, Drug, and Cosmetic Act permits a state-licensed pharmacy to prepare a customized version based on a prescriber's request. Montana recognizes this federally established practice and oversees compounded dapagliflozin preparations through the Montana Board of Pharmacy.

Two things matter for a patient considering this route. First, a compounded dapagliflozin product has not gone through FDA review for that specific formulation's safety, effectiveness, or bioequivalence to the approved tablet; 503A status describes a legal compounding pathway, not an FDA approval of the compounded product itself. Second, manufacturer savings cards and most insurance benefits do not apply to compounded products, so a lower sticker price at a compounding pharmacy needs to be weighed against the loss of those coverage pathways and against the absence of FDA bioequivalence data. Ask the compounding pharmacy directly about current USP compounding standards compliance and Montana licensure status rather than assuming any pharmacy calling itself a "503A pharmacy" meets every requirement.

Telehealth prescribing in Montana

Montana law broadly permits telehealth prescribing, and dapagliflozin does not carry a controlled-substance restriction that would require an in-person visit under federal telehealth rules. In practice, this means a Montana-licensed physician, nurse practitioner, or physician assistant can evaluate a patient by video visit, review labs (HbA1c, eGFR, urine albumin-to-creatinine ratio), and prescribe or continue dapagliflozin without requiring travel to a specialist. The exact statutory citation and any conditions tied to it should be verified with the Montana Board of Medical Examiners or a telehealth-specific legal summary rather than assumed from this article, since state telehealth statutes are periodically amended.

What this means for cost-reduction strategy

The realistic order of options, without attaching specific dollar figures that need verification, is:

1. If you have commercial insurance, ask your pharmacy whether Farxiga is covered and at what tier, and separately check AstraZeneca's current savings card terms, since commercial copay cards are typically the largest lever for insured patients.
2. If you are uninsured, check AstraZeneca's AZ&Me patient assistance program eligibility against the current HHS federal poverty guidelines, since income thresholds are usually expressed as a percentage of the poverty line and the poverty line itself is updated annually.
3. If you are on Montana Medicaid and dapagliflozin is not covered, ask your prescriber whether a prior authorization citing a heart failure or CKD indication (rather than diabetes alone) is worth pursuing, and separately ask about compounding as a fallback, understanding the bioequivalence and coverage tradeoffs above.
4. Discount cards (GoodRx-style programs) are worth checking as a bridge option while waiting on insurance approval, but they rarely beat manufacturer savings-card pricing for insured patients and their advertised prices change frequently.

Evidence boundary: what is established, what is not

Established: Dapagliflozin has FDA-approved indications for type 2 diabetes, heart failure (across ejection fraction categories), and chronic kidney disease. It is a brand-only oral SGLT2 inhibitor with no FDA-approved generic as of this writing. Compounding under 503A is a legitimate, federally recognized pathway when a licensed pharmacy and prescriber document clinical need.

Plausible but requiring current verification: Manufacturer copay-card and patient-assistance terms, Montana Medicaid's specific coverage decision for dapagliflozin, and individual commercial insurer formulary tier placement. These are real policies that exist somewhere in current, checkable documents, but this article cannot certify their exact current values.

Not established here: Specific cash-pay dollar prices at named Montana pharmacies, comparative pricing across neighboring states, exact enrollment numbers for Montana Medicaid, and any quoted statement attributed to a named physician about SGLT2 inhibitor access. These claims appeared in earlier drafts of this material without a verifiable source and have been removed rather than repeated.

Verification checklist: stable facts versus facts you must re-check

Use this before acting on any cost claim about Farxiga in Montana, including the ones above.

Stable (federal, unlikely to change week to week):

• Confirm current FDA-approved indications on the drug's official labeling
• Confirm there is still no FDA-approved generic dapagliflozin
• Confirm 503A compounding requires an individual prescription and a state-licensed pharmacy
• Confirm your prescriber (MD, DO, NP, or PA) holds active Montana licensure

Date-sensitive (recheck at time of fill, not from memory of a prior fill):

• Call your specific pharmacy for today's cash price if uninsured
• Confirm your commercial plan's current formulary tier for dapagliflozin for the current plan year
• Confirm whether step therapy or prior authorization currently applies on your plan
• Confirm Montana Medicaid's current preferred drug list status for dapagliflozin directly with Medicaid or your pharmacy
• Confirm AstraZeneca's current savings-card copay cap and eligibility rules on their official program page
• Confirm current AZ&Me income eligibility against this year's published federal poverty guidelines
• If considering a compounding pharmacy, confirm its current Montana Board of Pharmacy license status and ask directly about USP compounding standard compliance
• If using telehealth, confirm your prescriber's license covers your county and that no in-person visit requirement currently applies

If any answer above is "I'm not sure" or "I read it on a website," treat the underlying cost estimate as unverified until you get a direct answer from the payer, pharmacy, or state agency involved.

When to involve your prescriber or seek urgent care

Cost barriers should not lead to skipping doses or stopping dapagliflozin abruptly without medical guidance, particularly for patients taking it for heart failure or kidney disease rather than diabetes alone, since abrupt discontinuation can affect fluid status and kidney function trends that your prescriber is monitoring. Contact your prescriber if you cannot afford a refill, rather than stopping without discussion. Seek urgent care for signs of diabetic ketoacidosis (nausea, vomiting, abdominal pain, unusual fatigue) even with normal or near-normal blood glucose, since SGLT2 inhibitors carry a rare risk of euglycemic ketoacidosis, and for signs of a urinary or genital infection that worsens rapidly, or for symptoms of volume depletion such as dizziness or fainting, especially if you are also taking a diuretic.

References

2. Montana Board of Pharmacy. Pharmacy licensing and compounding oversight. https://boards.bsd.dli.mt.gov/pharmacy
3. U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. Federal poverty guidelines (updated annually). https://aspe.hhs.gov/

Trial names referenced above (DAPA-HF, DAPA-CKD, DECLARE-TIMI 58, CREDENCE) describe publicly known cardiovascular and renal outcomes studies of SGLT2 inhibitors. This draft does not cite specific journal URLs or numeric results for these trials because the identifiers available at the time of writing could not be independently confirmed as correct. A clinician or editor verifying this article should pull exact trial results directly from PubMed or the original journal before any specific hazard ratio or confidence interval is published on this page.